Skip to content
ATLAS PREP HQ
Longevity

FOXO4-DRI

D-retro-inverso FOXO4-derived peptide (Proxofim)

Experimental senolytic peptide research investigating selective removal of senescent cells.

Preclinical Evidence

Route

Subcutaneous in the community educational protocol

Common format

10 mg vial

Research focus

cellular senescence

Evidence level

Preclinical Evidence

Typical cycle

No established human cycle

Longevity research motifLongevity

FOXO4-DRI in 30 seconds

Atlas Fast Read

What it is

D-retro-inverso FOXO4-derived peptide (Proxofim)

Why people care

Experimental senolytic peptide research investigating selective removal of senescent cells.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

The key gaps are profound: no established human safety, uncertain senescent-cell selectivity across tissues, potential loss of beneficial senescence, immunogenicity, pharmacokinetics, and unknown cancer/wound-healing consequences.

Bottom line

FOXO4-DRI is a striking senolytic research tool in mice, but it sits near the extreme end of uncertainty for human use.

Overview

What is FOXO4-DRI?

FOXO4-DRI is d-retro-inverso FOXO4-derived peptide (Proxofim). Experimental senolytic peptide research investigating selective removal of senescent cells.

FOXO4-DRI gained attention after a 2017 senolytic study showed clearance of senescent cells in aged and progeroid mice. It remains an experimental research peptide without an established human development program.

Mechanism

How it works

Disrupts the FOXO4-p53 interaction in senescent cells. In mouse models this can free p53 to relocate and trigger apoptosis preferentially in senescent cells, producing a senolytic effect.

Research areas

cellular senescencesenolyticsfrailty modelstissue aging

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No established human clinical evidence demonstrates that FOXO4-DRI safely removes senescent cells or improves aging outcomes. It remains a preclinical senolytic concept.

Preclinical evidence

The landmark evidence is in aged and progeroid mice, where FOXO4-DRI reduced senescent-cell burden and improved some measures of tissue function and frailty. Human safety, selectivity, and durability are unknown.

Knowledge gaps

The key gaps are profound: no established human safety, uncertain senescent-cell selectivity across tissues, potential loss of beneficial senescence, immunogenicity, pharmacokinetics, and unknown cancer/wound-healing consequences.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 250–500 mcg/day with titration. There is no validated human dose.

Frequency

Once daily in the community research protocol.

Timing

No established time-of-day requirement.

Route

Subcutaneous in the community educational protocol; published landmark evidence is animal work.

Cycle length

No established human cycle

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid repeated freeze-thaw.

Monitoring

No validated human monitoring. If studied clinically, CBC/CMP and inflammatory markers would be basic safety context; senescent-cell biomarkers are not standardized for routine use.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety data are insufficient. Potential adverse effects include injection-site reactions, headache, fatigue, dizziness, nausea and unknown long-term effects on gene regulation, growth, metabolism or immune function.

Contraindications

No validated human contraindication profile exists. Avoid use outside research oversight in pregnancy/breastfeeding, active malignancy, significant organ disease or known hypersensitivity.

Interactions

Formal drug-interaction studies are absent or very limited. Interactions with anticancer, endocrine, metabolic and immunomodulatory therapies are unknown.

Stacks

Common stacks

FOXO4-DRI alone in preclinical research

Senolytic effects are preclinical and potentially high-risk; combination senolytic strategies should remain formal research questions.

No human stack is established.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

FOXO4-DRI is a striking senolytic research tool in mice, but it sits near the extreme end of uncertainty for human use. Removing senescent cells is not automatically beneficial in every tissue or context, and human selectivity and safety are unknown.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

Glutathione

Antioxidant research focused on redox balance, oxidative stress, and cellular detoxification pathways.

Read guide